Oyster Point Pharma, Inc

700 Alexander Park Drive Suite 301
Princeton, NJ 08540
United States

Tel: 609-382-9032

Show jobs for this employer

About Oyster Point Pharma, Inc

Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company’s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the Trigeminal Parasympathetic Pathway (TPP) to activate the glands responsible for tear film production. The parasympathetic nervous system (PNS) is part of the involuntary nervous system responsible for regulating homeostasis, the “rest and digest” system, and is an important pathway for basal tear film production. Oyster Point Pharma is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate tear film production in patients with Dry Eye Disease (DED).

Oyster Point Pharma, named after the Oyster Point waterfront on San Francisco Bay, was founded in 2015 and is headquartered in Princeton, New Jersey.


Twitter LinkedIn

107 articles about Oyster Point Pharma, Inc